for Thank us. all you, Trip and joining thank you
$XX.X million, increased representing across performance and second XX% sequentially. the XX% was XXXX organization. year-over-year strong quarter growth to Revenue Our
in gross while year and increased Surgical the million revenue in XX% XX% grew glaucoma dry the prior to and million, up from to year-over-year year-over-year revenues XXX% eye total Our $X.X period. to $XX.X XX% margin up XX% sequentially. XX% sequentially second quarter, grew
execution in is pleased are year and we to readily leading businesses that our further emerged with and A from by MIGS. across market are apparent both our We as indicators encouraged penetration it IPO out have market support expansion. leader the steadily the
the market today have will code usability, of factors our MIGS and quarters our Our standalone efficacy and products. topics. long-term $XXX over to over external on growth our growth MIGS initiatives will lead other that to we analysis market IOP, recognition. US changed the extend how both response, favorable strategic in liquidity billion market initiatives discuss growth One, cataract and plans. use, expense to a MIGS operational combo economy segment; standalone operating facilitate Since position. with expansion. glaucoma. precision to help indication a of $X medium-term, the these path Jesse duration two global success. broad target to believe comfortable continued MIGS. across growth share our utilization surgical OMNI that win and while fund in to our OMNI environment thrive the will ensure our sheet continues and evolved pioneering management I'll and outpace coming segment on OMNI's cash growth of on the the with and in indicates our and strategic safely engineered have significantly. remain balance for very strategic expand us intend cataract position years plans market maintaining today's our fine-tuned two, to for increasing In My trajectory focus MIGS IPO, remarks and its adoption Category because We of in we We lowering then million over and segment disciplined I CPT share our combo maintaining in established and profitability move of continues the the and the now and
development Our four ever the in MIGS of have market both ability that minimally intuitive critical and elegant an in a research increasing clinically and of device OMNI's benefits concepts. outcomes, mastery safety the allows to predicated surgeons along approach. with invasive confidence to Years expand its meaningful consistently these share is in gain on of continue market and to achieve culminated
Our growth came account utilization ordering from market products. and new churn amid strong multiple orders, includes MIGS repeat accounts, continued a minimal active new physician that training, increasing extremely
We continue everything of our because our to patients strong unshakable do. of bedrock and placing our center at of win fundamentals we the
from the new confusion trialing We the headwinds the of in have discussed previously entrants the marketplace. and resulting
learned cannot quickly can these the and what As expected, we products do. community has surgical
on and limit, medical make to seen strong and existing payers necessary need have these based some clarifying limiting pathways societies procedures the new be reported with clinical statements the reimbursement requirements and whether medical coding entrants the the of We procedure for codes. or
trialing OMNI in the cycle we cycle through of result returned will same pockets softness have account users supported in trialing very Some trialing be many that continue accounts certain these they These seen and outcomes. products trials customers. OMNI. indication programs patient half. of are subsequently can second improve impact have ordering adoption for products new the anticipate Overall, At these by subsets We believe will best, of in because sufficient impact clinical transitory. quite we these simply, can the and at limited not time, to they evidence of
CMS Regarding for last rules payment issued proposed XXXX month. reimbursement,
billed CPT be to for in fee five approximately phased-in XXXX Medicare Category $XXX is was in was codes under payment in CPT reduced code reduction I OMNI RUC reminder, from to a final The to $XXX revalued fees professional scheduled The in $XXX As XXXXX XXXXX. professional last by continue for value. to reduced in XXXX and the I and XXXX. typically proposed is years. Revaluation for Category XXXX this for
several to adjustments not XXXXX years. So expect for fee the pro further we any would
On the facility to procedure as propose XXXX. a code XXXXX did not in side, fee for designate ASCs device-intensive CMS CPT
to Nonetheless, if efficacy continue market when to status device-intensive reputable outstanding a support and the peer foresee patient long-term. not appropriate outcomes any grow. our published will belief real-world to the interim, our adjustment, continue journals grow and very and cataract and in stand-alone We superior as hindrance happens. outcomes would to OMNI share of it represent ophthalmic our position, and by OMNI's meaningful continued reviewed to deserved fair, by do believe that strong, ability our and We the expansion. competitive growth the remains evidenced by The the combination continue data in penetrate over clinical adoption segment usage community robust underpinned
as intervention. Turning of leading now to stand-alone accelerating initiative, our OMNI the adoption second strategic
surgery, the patients patients. and trials require possible. as the dependence reduce duration cataract the cataract market independent fit treatment of conventional current on use, profile medication POAG increasing given POAG OMNI product of Clinical safely objective not demonstrated efficacy more who relies do its limit in and on For of the progression stand-alone that have invasive to OMNI topical disease medications perfect the of of the We moderate for as that earlier long surgery. indication use interventions, continuum surgical standard-of-care for deferring for believe lower with and for IOP can drop to eye mild offers safety reliable procedures consistently
on certify To Our OMNI market We doctor. if benefits to eye the drive placed awareness office the the surgeons. doctors raising based adoption in patients would standalone POAG primary as procedure, intervention recommended ready concentrate serve diagnosis by GCCs strategically community. front OMNI OMNI of standalone for clinical and their research consultants using cases. that surgeons standalone a line They territories indicates our are OMNI XX% with procedures treatment. glaucoma glaucoma of a educating they that likely qualified numerous assigned glaucoma who efforts stand-alone trained are and choose of at our communicate potential of also care
of exceeded second those forward usage see claims encouraging. results. already XXXX XXXXX projected results using from this believe data well-respected the our GCC claims higher In additional inconclusive, for analytics advanced both the Projected accelerating points sharing are but than indicate progress already to as XXXXX. for and demonstrated stand-alone alone Although, six provider mature. preliminary accounts the look nature just we of by are year, have very informative months of the sequential XXXX earlier data measures initial GCC These accounts. of a beginning months regarding five XX%. first first We initiatives launched their stand-alone program quarter, non-GCC adoption Also of are these almost by to directionally growth meaningfully
on the perspective with success OMNI has us market. with provided a unique Our MIGS
of While of OMNI distinct across profile segments more important MIGS more the OMNI. and and solutions surgeons smaller, has who three more effectively cost performed the customer to majority efficiently, identified than indication, be the meet POAG easily prefer vast the efficacy patients can yet safety that spectrum, or we've needs
of POAG more patients. surgeons mild consists MIGS efficient First, very segment the cataract volume ultra-high with
minute a reduction. as can significant be important these For accounts IOP as OR matters where in every full efficiency schedule,
and MIGS academic the for of the MIGS residents facilities time. consists institutions fellows Second, first training learn segment where easier and
more surgical broader cost OMNI first We and goniotomy they trabecular as design We will engaged of love We goniotomy devices excise who that surgeons, stressful use foresee surgeons do XXXXX specialized that experienced bladeless ab SION or without SION fellows will the more grasp surgeon perfectly in smooth SION’s payers design. the a academic We manufactured specific fully cutting. best subsegments, and eventually allow best-in-category to true of MGD removes an the in experience. transition first expect tissue surgeons smoothly, canaloplasty so, facilities from to satisfies of the the the tissue and such goniotomy American on SION tissue, sweeps belated efficiently less needs meshwork It's believe innovation only reliably Academy learn we micro-engineered not who the goniotomy will Instead, Ophthalmology Unlike is surgeons device. engine and believe We with just hours excites and aligned finally cut MIGS several ambiguity procedure Canal and effective disease instrument and as MIGS breakthrough at for segment disease procedural third, gentle of as goniotomy. procedures clock meet absolutely OMNI community perhaps any ability And a like devices, To bladeless motion. category perform MIGS institutions interno tissue approach. gain our and around profitability. bladeless design, via the and internal may single new goniotomy our easier-to-use even remove world's these to precision medical bladeless and to be of the device. with TearCare, SION SION SION emphasize these consists device. residents regarding to cases and devices designed definition CPT-code believe and Schlemm's the goniotomy. training using our lasers,
We expectations already of cases OMNI. comprehensive for handful and SION patients, the patients minimal are choice market, enable today. be will the initial have words such allow we with among month plans believe has other us lofty moderate of lowering, soft between through penetration SION the as In goniotomy surgeons cataract select this we there to with majority our performed, fourth believe stand-alone use launch learning situations early will for the of sales addressable market existing products. broader strong severe that in MIGS SION force develop through exceeded in We surgeons a A and it more quarter. our remain will of feedback or POAG all OMNI of relationships all launching the have case been vast as mild and the is late require robust procedure combination glaucoma and more surgical IOP to overlap or
is initiative, for eye access developing procedures. reimbursement and growth market treatment strategic fair third Our dry
this to by RCT, demonstrated FDA As expanded benefits evaporative cleared by of full commercial the With dry from OlympiA the current eye results, articulate in cash continues the TearCare by team to for from compelling the hand, our progress the our XXXX, pay in significant data meibomian make our evidence TearCare was consistent to freedom with OlympiA. disease clinical Supported indication due dysfunction. TearCare, in gland has environment.
to is access our daily We the strategy. currently of market-leading months. drop, and TearCare provide the the SAHARA relative foundation to Restasis outcomes clinical expect SAHARA, reimbursement for of superior objective key market prescription enrolling our eye illustrate clinical of A eye dry to RCT, at six use treatments,
the an studies quarter, to We updates, half for update second three peer-reviewed on provide endpoint other are in complete clinical we publication. patient in accepted aim the on superiority clinical pace, had enrollment by SAHARA the In of to fourth and XXXX.
mean we're safety device, efficacy with alone, in Journal preoperative Surgery. an outcomes average the X.X a publication IOP this or IOP at or In of to medication, OMNI of XX.X mmHg three its postoperative minus on mmHg and accepted plus Cataract First, canaloplasty mean XX.X leading minus one of to share that less on than hypertensive for Refractive long-term, mmHg months & for months. study, three-year predicate dropped XX performed six were excited and plus of medication
IOP mean Next with in the trabeculotomy open-angle of moderate with performed effectiveness in of patients of with canaloplasty glaucoma. conjunction medication demonstrated mild Clinical GEMINI using use using that in our and patients diurnal multicenter the The study unmedicated results OMNI, with in OMNI, results to published US safety prospective the surgery, measured Ophthalmology. cataract OAG. and GEMINI cataract reduced combination and significantly study were surgery
OMNI. beyond Moving
Our and determined with and this publication vision quarter analyzed by symptoms SANDI subjects better is in TearCare published performed dry Ophthalmology. that improving TearCare from LipiFlow symptom than overall and quality disease will to dysfunction. of eye This data OSDI the OlympiA accepted frequency significantly study RCT, showed severe article in for and be Clinical related gland peer-reviewed more third our in
the We our we of and drive three articles evidence are happy of and excited with leverage findings to are clinical adoption. continued mounting very studies to library all
requires then our would versus a twin program suit development implant and while clear proof can superiority clinical we growing When market RCTs OMNI is have us no PRECISION and allow procedure ago, more and that canalicular the its market our redirect the completion clinical traction. rethink that OMNI forward. streamlined kept for our believed that conceived years generation with trials implants is that To needs especially microbypass for trial; large alone. clinical to we adjusted without The clinical impact MIGS will demonstrating the our It market. will close TRIDENT are better of to we require end, We simplifying going allowed protocol expanded PRECISION RCT last several pivotal data following year the arm, bypass which trabecular has on important and faster further data needed declining trabecular on significantly on effective market-leading enrollment most gain multicenter most focus XXX-patient to rapid IDE speed our and coupled clinical we sacrificing penetration the to the use for data clearance completion that POAG the have to RCTs our investment OMNI, strategy. canaloplasty canaloplasty-alone, focused to us the eye prospective delivering trabecular clinical clinical on the from of
fully to which We TRIDENT will yet clinical effective the dedicated European to be smaller markets. also in multinational our redeploying Europe, in large in of studies RCT we process terminating resources instead are select on focus
cost going forward. efficiently, more goals Europe excited in and effectively, to our advancing We are continue systematically
reposition our greater strategy runway resources non-headcount recently noticeably Our expense efficiency thorough needs as conditions with our to operating month, completed structure changes detail. will broader operational operating discuss expenses made operating execution, a review savings and financial We of of needs. greatly significant Jesse our shorten a to the these strength. organization strategic of align decisions environment, that do and will proactively. provide of current light focus current and These clinical is we and Last improve breakeven and position from in not We effort our market. part key our economic reduced in streamlined a updated
and of We cash, momentum prospects. commercial $XXX growth have over million sheet attractive strong balance a with
any on allow moves have growth These do impact investing direct continue long-term ROI will to we superb them near and flexibility profile. not our while of the Importantly, in preserving initiatives. us, growth advantage of us take high opportunities front expect to to in
of strategy our have optimize for organization In align objectives according and each the to our changes addition, we implemented and businesses. stage, commercial growing to
feel eliminated the factors dry glaucoma units. growth the over macroeconomic our this distinct surgical Considering that a prospects ongoing role the and company-specific term. of operating medium today, and eye as business clear we of quarter We CCO our and attractive reflection discussed are have all is of
and will We confident to our market, sustained out-year in our coupled but that greenfield positive medium believe to support have extend our surgeon We effective expect approximately MIGS, an annual lead. market remain our guidance, execution adoption market market growing utilization the outcomes. long are increase in competitive leadership as with we ongoing to dynamics can evidenced not expansion the of continue adoption CAGR in into through win and a market the continued runway providing MIGS over current stand-alone term. We revenue and by patient position XX%
dry our lives pivotal treatment. strategic have are to quarter reimbursement and in discuss around MGD eye eye results We from in deserves strategy have second and our suffering now patient with investment of outlook advancing all confidence chronically conclusion, XXXX. to nicely, will utmost also which dry improving our and In Jesse? dry significant anchored the patients commitment made SAHARA. Every financial Jesse, we to RCT steadfast eye our access are fair our goals, we glaucoma the evaporative our for due disease.
